No description available.

Made available in DSpace on 2014-06-12T23:03:34Z (GMT). No. of bitstreams: 2 arquivo8768_1.pdf: 1004395 bytes, checksum: 90d0ce08fa2d061dd3825bdc0d320505 (MD5) license.txt: 1748 bytes, checksum: 8a4605be74aa9ea9d79846c1fba20a33 (MD5) Previous issue date: 2004 / Trezentas e vinte e nove (329) crianças de 1 a 6 anos de idade, de 6 creches da Prefeitura da Cidade do Recife, foram submetidas a avaliação inicial do estado nutricional de ferro, pelos níveis de hemoglobina, e, divididas em três grupos, receberam, durante 30 dias, suplemento alimentar de 500μg de molibdênio (MO 105 crianças), 500μg de molibdênio e 15mg de sulfato ferroso (SFMO 91 crianças) ou somente 15mg de sulfato ferroso (SF 133 crianças), de segunda a sexta. Após trinta dias de consumo diário dos esquemas de suplementação, somente foi possível coletar material para avaliação em 159 crianças (50 no grupo MO, 48 no SFMO e 61 no SF), amostra que se tomou para comparação dos dois momentos da pesquisa. No geral, o segundo momento revelou que 81% das crianças apresentaram nível de hemoglobina acima de 11g/dl. O perfil de cada grupo mostrou que a anemia foi controlada em 52%, 82% e 79%, nos grupos MO, SF e SFMO, respectivamente, e a média de hemoglobina aumentou de 10,78 ± 1,3g/dl para 11,73 ± 1,4 g/dl no grupo MO, de 9,84 ± 1,7 g/dl para 11,75 ± 0,76 g/dl no grupo SF e de 10,72 ± 1,15 g/dl para 12,14 ± 0,83 g/dl no grupo SFMO. Pelo aumento significativo dos níveis de hemoglobina e pelo deslocamento da curva de distribuição de freqüência, conclui-se que o molibdênio se revelou biologicamente ativo e eficaz no tratamento da anemia

No description available.

No description available.

The genetic factors controlling Mixed Function Oxidase (MFO) Activity and malathion resistance was studied in the larva and the adult of a malathion resistant strain of Drosophila melanogaster. In addition, the developmental expression and tissue localization of high MFO activity was characterized in the larva and the adult. Microsomal extracts from a strain with a resistant second chromosome were found to have increased amounts of protein with a relative molecular mass of 52 kD, while a strain with a resistant third chromosome was found to have increased amounts of proteins with relative molecular masses of 51 and 55 kD in the microsomal extract. MFO activity associated with a strain with a resistant second chromosome was found to be most concentrated in the intestine and abdominal wall of the imago, while found primarily in the malpigian tubules and the fat body of the larva. The mapping of genes on the second chromosome associated with larval resistance to malathion suggested two loci, a major resistance gene at 2-64 cM and a second minor resistance gene. The mapping of genes on the second chromosome associated with adult resistance again suggested two loci, one at 2-64 cM and a second just to the left of the marker black (48.5 cM). The mapping of genes on the second chromosome associated with high PNA demethylase activity (an MFO activity) in the adult suggested a locus at 2-64 cM and a second between 54.5 and 60.0 cM. The locus at 2-64 cM and a third locus between 48.5 and 51 cM was found to be associated with high 7-EC hydroxylase activity ( a second MFO activity) in the adult. / Thesis / Master of Science (MS)

Doctor of Philosophy / Biochemistry and Molecular Biophysics / Michael R. Kanost / Typical multicopper oxidases (MCOs) have ten conserved histidines and one conserved cysteine that coordinate four copper atoms, which are required for oxidase activity. During our studies of insect MCOs, we discovered a gene that we named multicopper oxidase-related protein (MCORP). MCORPs share sequence identity with MCOs, but lack many of the copper-coordinating residues. We identified MCORP orthologs in many insect species, but not in other invertebrates or vertebrates. We purified recombinant Tribolium castaneum (red flour beetle) MCORP. As expected, no oxidase activity was detected. We analyzed expression profiles of TcMCORP and Anopheles gambiae (African malaria mosquito) MCORP. They are constitutively expressed at a low level in many tissues, including ovaries. TcMCORP larval RNAi led to 100% mortality before adult stage. These deaths occurred during the larval to pupal and pupal to adult molts. Pharate pupal RNAi resulted in 20% mortality during the pupal to adult molt, and 100% mortality by one month after adult eclosion. In addition, knockdown of TcMCORP in females prevented oocyte maturation, thus greatly decreasing the number of eggs laid. These results indicate that TcMCORP is an essential gene and that its function is required for reproduction. An understanding of the role MCORP plays in insect physiology may help to develop new strategies for controlling insect pests. A multicopper oxidase-1 (MCO1) ortholog has been identified in all insect species examined so far; thus, MCO1 probably has a conserved physiological function in insects. Most of the well-studied MCOs are laccases, ferroxidases, or ascorbate oxidases. Previously we found Drosophila melanogaster MCO1 has ferroxidase activity and we identified three putative iron binding residues in DmMCO1. Our kinetic analysis of recombinant MCO1 from Drosophila melanogaster, Anopheles gambiae, Tribolium castaneum and Manduca sexta showed that MCO1 orthologs are much better at oxidizing ascorbate than laccase substrates or ferrous iron, suggesting that MCO1 orthologs function as ascorbate oxidases. The putative iron binding residues are required for ascorbate oxidase activity but not ferroxidase and laccase activities. Ascorbate oxidases have been identified only in plants. This is the first identification of ascorbate oxidase in insects. Further studies are needed to understand their physiological function in insects.

BACKGROUND AND RATIONALE Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder affecting the central nervous system, primarily, the substantia nigra. It is characterized by loss of dopaminergic neurons in the nigro-striatal pathway, and ultimately patients with Parkinson’s disease may lose up to 80% of their dopamine-producing cells in the brain. Symptoms include bradykinesia, muscle rigidity, resting tremor and impaired postural balance. Symptomatic relief is obtained by using levodopa and various adjunct therapy including dopamine agonists, catechol-O-methyltransferase inhibitors and monoamine oxidase B inhibitors. Levodopa is used as the gold-standard for treatment of this disease. It effectively controls motor symptoms, however, motor complications that impair the quality of life develop with continued levodopa use. No treatments currently available can halt disease progression, therefore novel drugs that can slow down or stop disease progression are urgently required. The monoamine oxidase (MAO) A and B enzymes are flavoenzymes that play an important role in the oxidative degradation of amine neurotransmitters such as dopamine, serotonin and epinephrine. Early attempts to block dopamine metabolism in the brain using nonselective MAO inhibitors was effective but led to side effects such as hypertensive crisis, thus they lost favor. The MAO-B enzyme is of particular importance in Parkinson’s disease because it is more active than MAO-A in the basal ganglia, and is thus primarily responsible for the catabolism of dopamine in the brain. Selegiline and rasagiline, both irreversible, selective MAO-B inhibitors have proven efficacy in symptomatic treatment of Parkinson’s disease, but due to the irreversible nature of their binding, it can take several weeks after treatment termination for the enzyme to recover. Use of reversible inhibitors such as lazabemide and safinamide do not have this disadvantage, and have safer side effect profiles. Unfortunately, clinical trials for lazabemide use in Parkinson’s disease have been discontinued. Therefore, due to the lack of disease modifying agents for Parkinson’s disease, as well as safety concerns of current PD therapy, an urgent need exists for novel, safe and efficient MAO inhibitors. Current research is thus aimed at designing selective or non-selective reversible inhibitors that bind competitively to the enzyme. The MAO inhibitory potential of chromone derivatives has been illustrated previously. Evaluation of C6- and C7-alkyloxy substituted chromones, for example revealed that these compounds were potent, selective and reversible MAO-B inhibitors. It has further been shown that chromone 3-carboxylic acid is a potent selective, irreversible MAO-B inhibitor. Phenylcarboxamide substitution in position 3 of chromone 3-carboxylic acid also results in potent, selective MAO-B inhibitory activity. Therefore, further evaluation of the effect of substitution with flexible side chains in the 3-position to evaluate MAO-B inhibition is of importance. The chromone ring system is thus a privileged scaffold for the design of inhibitors that are selective for MAO-B and has the additional advantages of generally exhibiting low mammalian toxicity and ease of synthesis. AIM The aim of this study was to design, synthesize and evaluate novel chromone derivatives as inhibitors of monoamine oxidase. RESULTS Design and Synthesis 3-Aminomethylene-2,4-chromandiones and ester chromone derivatives were synthesized by coupling several aromatic and aliphatic amines and alcohols, to chromone 3-carboxylic acid, in the presence of CDI (carbonyldiimidazole). 15 Compounds were successfully synthesized and characterized by using NMR and IR spectroscopy, as well as mass spectrometry. X-ray crystallography was used to obtain a crystal structure for the 3-aminomethylene-2,4- chromandione derivative, 46, in a bid to verify the structures of the synthesized compounds. Melting points of all compounds were determined, and the purity determined using HPLC techniques. MAO inhibition studies A fluorometric assay was employed using kynuramine as substrate, to determine the IC50 (50% inhibition concentration) values and SI (selectivity index) of the synthesized compounds. Generally, the esters exhibited weak MAO-A and MAO-B inhibition, while the 3- aminomethylene-2,4-chromandione derivatives showed promise as selective MAO-B inhibitors, with IC50 values in the micromolar range. Compound 38, 3- [(benzylamino)methylidene]-3,4-dihydro-2H-1-benzopyran-2,4-dione, was the most potent MAO-B inhibitor with an IC50 value of 0.638 μM and a SI of 122 for MAO-B inhibition. Interesting trends were revealed through analysis of the structure activity relationships, for example, for the 3-aminomethylene-2,4-chromandione derivatives, the presence of a chlorine moiety in the side chains of the compounds resulted in a decrease of MAO-B inhibition activity. Chain elongation further also resulted in weakening the MAO-B inhibition activity, while chain elongation in the ester derivatives led to a slight increase in MAO-B inhibition activity. Reversibility studies The reversibility of binding of the most potent compound in the 3-aminomethylene-2,4- chromandione series, 38, was evaluated. None of the synthesized inhibitors were potent MAO-A inhibitors, therefore reversibility of MAO-A inhibition was not examined. Recovery of enzyme activity was determined after dialysis of the enzyme-inhibitor complexes. Analysis of the kinetic data obtained showed that MAO-B catalytic activity was recovered to 115% of the control value. This suggests that compound 38 is a reversible inhibitor of MAO-B. Mode of inhibition A set of Lineweaver-Burk plots were constructed to determine mode of inhibition of compound 38. The results show linear lines that intersect at a single point just to the left on the y-axis. This indicates that compound 38 interacts competitively with the MAO-B enzyme. In conclusion, chromone derivatives were synthesized and evaluated as inhibitors of MAO. Compound 38 was the most potent MAO-B inhibitor with an IC50 value of 0.638 μM. The effect of chain elongation and introduction of flexible substituents in position 3 of the chromone 3-carboxylic acid nucleus was explored and the results showed that 3- aminomethylene-2,4-chromandione substitution is preferable over ester substitution. / MSc (Pharmaceutical Chemistry), North-West University, Potchefstroom Campus, 2015

BACKGROUND AND RATIONALE Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder affecting the central nervous system, primarily, the substantia nigra. It is characterized by loss of dopaminergic neurons in the nigro-striatal pathway, and ultimately patients with Parkinson’s disease may lose up to 80% of their dopamine-producing cells in the brain. Symptoms include bradykinesia, muscle rigidity, resting tremor and impaired postural balance. Symptomatic relief is obtained by using levodopa and various adjunct therapy including dopamine agonists, catechol-O-methyltransferase inhibitors and monoamine oxidase B inhibitors. Levodopa is used as the gold-standard for treatment of this disease. It effectively controls motor symptoms, however, motor complications that impair the quality of life develop with continued levodopa use. No treatments currently available can halt disease progression, therefore novel drugs that can slow down or stop disease progression are urgently required. The monoamine oxidase (MAO) A and B enzymes are flavoenzymes that play an important role in the oxidative degradation of amine neurotransmitters such as dopamine, serotonin and epinephrine. Early attempts to block dopamine metabolism in the brain using nonselective MAO inhibitors was effective but led to side effects such as hypertensive crisis, thus they lost favor. The MAO-B enzyme is of particular importance in Parkinson’s disease because it is more active than MAO-A in the basal ganglia, and is thus primarily responsible for the catabolism of dopamine in the brain. Selegiline and rasagiline, both irreversible, selective MAO-B inhibitors have proven efficacy in symptomatic treatment of Parkinson’s disease, but due to the irreversible nature of their binding, it can take several weeks after treatment termination for the enzyme to recover. Use of reversible inhibitors such as lazabemide and safinamide do not have this disadvantage, and have safer side effect profiles. Unfortunately, clinical trials for lazabemide use in Parkinson’s disease have been discontinued. Therefore, due to the lack of disease modifying agents for Parkinson’s disease, as well as safety concerns of current PD therapy, an urgent need exists for novel, safe and efficient MAO inhibitors. Current research is thus aimed at designing selective or non-selective reversible inhibitors that bind competitively to the enzyme. The MAO inhibitory potential of chromone derivatives has been illustrated previously. Evaluation of C6- and C7-alkyloxy substituted chromones, for example revealed that these compounds were potent, selective and reversible MAO-B inhibitors. It has further been shown that chromone 3-carboxylic acid is a potent selective, irreversible MAO-B inhibitor. Phenylcarboxamide substitution in position 3 of chromone 3-carboxylic acid also results in potent, selective MAO-B inhibitory activity. Therefore, further evaluation of the effect of substitution with flexible side chains in the 3-position to evaluate MAO-B inhibition is of importance. The chromone ring system is thus a privileged scaffold for the design of inhibitors that are selective for MAO-B and has the additional advantages of generally exhibiting low mammalian toxicity and ease of synthesis. AIM The aim of this study was to design, synthesize and evaluate novel chromone derivatives as inhibitors of monoamine oxidase. RESULTS Design and Synthesis 3-Aminomethylene-2,4-chromandiones and ester chromone derivatives were synthesized by coupling several aromatic and aliphatic amines and alcohols, to chromone 3-carboxylic acid, in the presence of CDI (carbonyldiimidazole). 15 Compounds were successfully synthesized and characterized by using NMR and IR spectroscopy, as well as mass spectrometry. X-ray crystallography was used to obtain a crystal structure for the 3-aminomethylene-2,4- chromandione derivative, 46, in a bid to verify the structures of the synthesized compounds. Melting points of all compounds were determined, and the purity determined using HPLC techniques. MAO inhibition studies A fluorometric assay was employed using kynuramine as substrate, to determine the IC50 (50% inhibition concentration) values and SI (selectivity index) of the synthesized compounds. Generally, the esters exhibited weak MAO-A and MAO-B inhibition, while the 3- aminomethylene-2,4-chromandione derivatives showed promise as selective MAO-B inhibitors, with IC50 values in the micromolar range. Compound 38, 3- [(benzylamino)methylidene]-3,4-dihydro-2H-1-benzopyran-2,4-dione, was the most potent MAO-B inhibitor with an IC50 value of 0.638 μM and a SI of 122 for MAO-B inhibition. Interesting trends were revealed through analysis of the structure activity relationships, for example, for the 3-aminomethylene-2,4-chromandione derivatives, the presence of a chlorine moiety in the side chains of the compounds resulted in a decrease of MAO-B inhibition activity. Chain elongation further also resulted in weakening the MAO-B inhibition activity, while chain elongation in the ester derivatives led to a slight increase in MAO-B inhibition activity. Reversibility studies The reversibility of binding of the most potent compound in the 3-aminomethylene-2,4- chromandione series, 38, was evaluated. None of the synthesized inhibitors were potent MAO-A inhibitors, therefore reversibility of MAO-A inhibition was not examined. Recovery of enzyme activity was determined after dialysis of the enzyme-inhibitor complexes. Analysis of the kinetic data obtained showed that MAO-B catalytic activity was recovered to 115% of the control value. This suggests that compound 38 is a reversible inhibitor of MAO-B. Mode of inhibition A set of Lineweaver-Burk plots were constructed to determine mode of inhibition of compound 38. The results show linear lines that intersect at a single point just to the left on the y-axis. This indicates that compound 38 interacts competitively with the MAO-B enzyme. In conclusion, chromone derivatives were synthesized and evaluated as inhibitors of MAO. Compound 38 was the most potent MAO-B inhibitor with an IC50 value of 0.638 μM. The effect of chain elongation and introduction of flexible substituents in position 3 of the chromone 3-carboxylic acid nucleus was explored and the results showed that 3- aminomethylene-2,4-chromandione substitution is preferable over ester substitution. / MSc (Pharmaceutical Chemistry), North-West University, Potchefstroom Campus, 2015

No description available.

No description available.